Vivus Says EU to Recommend Against Approving New Diet Drug Qsymia

On September 21st, 2012, BusinessWeek reported that Vivus Inc. believes advisers to the European Union's health agency will recommend against approving its new diet drug Qsymia. One of the drug's two main ingredients, phentermine, was part of the popular obesity drug Fen Phen. Fen Phen was withdrawn from the market in 1997 after it was linked with heart valve damage and primary pulmonary hypertension (PPH). Now, AttorneyOne.com, a recognized authority on law, can provide helpful, proven advice and simple solutions including how to get in contact with legal counsel so anyone can easily and inexpensively deal with cases of Fen Phen severe adverse events. [http://www.attorneyone.com/fen-phen-lawsuits/

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Fen Phen: severe adverse events threat

Fen Phen: severe adverse events threat

Fen Phen was withdrawn from the market in 1997 after it was linked with heart valve damage

San Diego, CA (PRWEB) October 10, 2012

The media spotlight is often a double-edged sword. No one knows this better than people who suffer from Fen Phen adverse events. And yet, gossip and rumor-mongering aside, the real story here is being overlooked according to Sean Burke of AttorneyOne.

On September 21st, 2012, BusinessWeek reported that Vivus Inc. believes advisers to the European Union's health agency will recommend against approving its new diet drug Qsymia. The panel’s recommendation is expected in October. One of the drug's two main ingredients, phentermine, was part of the popular obesity drug Fen Phen.

As BusinessWeek mentions, Fen Phen was withdrawn from the market in 1997 after it was linked with heart valve damage. Findings of the November 2008 study, published in BMC Medicine, indicate that many individuals that had taken Fen Phen in the past were found to have heart valve damage up to 7 years later.

AttorneyOne.com, a recognized authority on law, can provide helpful advice and simple solutions including how to get in contact with legal counsel so that, in case of severe adverse events from Fen Phen, someone can easily and inexpensively deal with it. As Mr. Burke, director of Media Relations for AttorneyOne.com, added, “What all this information really illustrates is that threat from Fen Phen remains. For that reason, our focus should squarely fall on getting the word out and assisting people in finding the right legal assistance.”

As BusinessWeek reported on August 30th 2012, Pfizer Inc. whose Wyeth unit reserved more than $21 billion to settle lawsuits over the Fen Phen drug, lost its bid to have claims that the pills caused a fatal disease years after users stopped taking them thrown out (MDL No. 1203, US District Court for the Eastern District of Pennsylvania).

AttorneyOne.com has further information on Fen Phen lawsuits including how to get in contact with legal counsel.

Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2012/10/prweb9949261.htm.